U.S. to Get Fewer Vials of Pfizer COVID-19 Vaccine
MONDAY, Jan. 25, 2021 -- Pfizer will provide fewer vials of its COVID-19 vaccine to the United States in the coming months after it was discovered that it had previously shipped extra doses.
In December, U.S. pharmacists found that they could get an extra dose out of Pfizer vials that were supposed to contain only five doses, The New York Times reported.
The U.S. Food and Drug Administration has agreed with Pfizer's demand to formally acknowledge that those vials contained six doses instead of five. That means that Pfizer will count the extra dose toward its previous commitment of 200 million doses for the United States by the end of July and will provide fewer vials by that time than had been anticipated, The Times reported.
But pharmacists at some vaccination sites say it is a challenge to reliably extract the extra dose out of vials. Doing so requires a specialty syringe. "Now there's more pressure to make sure that you get that sixth dose out," Michael Ganio, senior director for pharmacy practice and quality at the American Society of Health-System Pharmacists, told The Times.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
MONDAY, March 1, 2021 -- Walmart said it will expand its COVID-19 vaccination program to more than 1,400 pharmacies in 35 states. The retailer will also partner with local...
MONDAY, March 1, 2021 -- A COVID-19 vaccine still awaiting U.S. Food and Drug Administration approval may prove to be a powerful weapon in fighting the pandemic, according to its...
MONDAY, March 1, 2021 -- The Janssen COVID-19 vaccine received the third emergency use authorization for a vaccine to prevent COVID-19, the U.S. Food and Drug Administration...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.